<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04890873</url>
  </required_header>
  <id_info>
    <org_study_id>ERX1000-C-002</org_study_id>
    <nct_id>NCT04890873</nct_id>
  </id_info>
  <brief_title>ERX1000 - Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Male and Female Subjects With Obesity</brief_title>
  <official_title>ERX1000 - A Phase I, Double-blind, Placebo-controlled, Single and Multiple Oral Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Male and Female Subjects With Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ERX Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ERX Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to assess the safety and tolerability of single and multiple oral&#xD;
      doses of ERX1000 in obese subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 19, 2021</start_date>
  <completion_date type="Anticipated">March 25, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 25, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A (Single Dose Group A9): Incidence and severity of adverse events (AEs)</measure>
    <time_frame>Day 1 up to end of study (Day 10)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A (Single Dose Group A9): Incidence of clinical laboratory abnormalities</measure>
    <time_frame>Screening (Day -28) up to end of study (Day 10)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A (Single Dose Group A9): Incidence of 12-lead electrocardiogram (ECG) abnormalities</measure>
    <time_frame>Screening (Day -28 to Day -2), Days 1, 3 and 10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A (Single Dose Group A9): Incidence of vital sign abnormalities</measure>
    <time_frame>Screening (Day -28 to Day -2), Check-in (Day -1), Days 1, 3, 4, 5, 6 and 10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A (Single Dose Group A9): Incidence of physical examination abnormalities</measure>
    <time_frame>Check-in (Day -1), Days 6 and 10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B (Multiple Dose Group B5): Incidence of 12-lead electrocardiogram (ECG) abnormalities</measure>
    <time_frame>Screening (Day -28 to Day -3), Check-in (Day -2), Days 1, 4, 7, 10, 19, 25, 28, 30 and 37</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B (Multiple Dose Group B5): Incidence of vital sign abnormalities</measure>
    <time_frame>Screening (Day -28 to Day -3), Check-in (Day -2), Days 1, 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, 15, 16, 19, 22, 25, 28, 30 and 37</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B (Multiple Dose Group B5): Incidence of physical examination abnormalities</measure>
    <time_frame>Check-in (Day -2), Days 30, 33 and 37</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B (Multiple Dose Group B6): Incidence of 12-lead electrocardiogram (ECG) abnormalities</measure>
    <time_frame>Screening (Day -28 to Day -3), Check-in (Day -2), Days 1, 4, 7, 10, 19, 25, 30 and 37</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B (Multiple Dose Group B6): Incidence of vital sign abnormalities</measure>
    <time_frame>Screening (Day -28 to Day -3), Check-in (Day -2), Days 1, 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, 15, 16, 19, 22, 25, 28, 29, 30 and 37</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B (Multiple Dose Group B6): Incidence of physical examination abnormalities</measure>
    <time_frame>Check-in (Day -2), Days 30, 34 and 37</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B (Multiple Dose Group B5 and Multiple Dose Group B6): Incidence and severity of adverse events (AEs)</measure>
    <time_frame>Day 1 up to end of study (Day 37)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B (Multiple Dose Group B5 and Multiple Dose Group B6): Incidence of clinical laboratory abnormalities</measure>
    <time_frame>Screening (Day -28) up to end of study (Day 37)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part A (Single Dose Group A9): Plasma pharmacokinetic (PK) outcome endpoint of ERX1000, AUC0-t</measure>
    <time_frame>Day 1, 8 and 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A (Single Dose Group A9): Plasma PK outcome endpoint of ERX1000, AUC0-∞</measure>
    <time_frame>Day 1, 8 and 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A (Single Dose Group A9): Plasma PK outcome endpoint of ERX1000, AUC0-τ</measure>
    <time_frame>Day 1, 8 and 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A (Single Dose Group A9): Plasma PK outcome endpoint of ERX1000, Cmax</measure>
    <time_frame>Day 1, 8 and 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A (Single Dose Group A9): Plasma PK outcome endpoint of ERX1000, trough (predose) plasma concentration (Ctrough)</measure>
    <time_frame>Day 1, 8 and 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A (Single Dose Group A9): Plasma PK outcome endpoint of ERX1000, Tmax</measure>
    <time_frame>Day 1, 8 and 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A (Single Dose Group A9): Plasma PK outcome endpoint of ERX1000, time of last measurable concentration (tlast)</measure>
    <time_frame>Day 1, 8 and 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A (Single Dose Group A9): Plasma PK outcome endpoint of ERX1000, t1/2</measure>
    <time_frame>Day 1, 8 and 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A (Single Dose Group A9): Plasma PK outcome endpoint of ERX1000, apparent total plasma clearance (CL/F)</measure>
    <time_frame>Day 1, 8 and 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A (Single Dose Group A9): Plasma PK outcome endpoint of ERX1000, apparent volume of distribution (Vz/F)</measure>
    <time_frame>Day 1, 8 and 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A (Single Dose Group A9): Plasma PK outcome endpoint of ERX1000, accumulation ratio (AR).</measure>
    <time_frame>Day 1, 8 and 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A (Single Dose Group A9): Urine PK outcome endpoint of ERX1000, amount of drug excreted in urine over the sampling period (Aeu)</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A (Single Dose Group A9): Urine PK outcome endpoint of ERX1000, percentage of dose excreted in urine over the sampling interval (%Feu)</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A (Single Dose Group A9): Urine PK outcome endpoint of ERX1000, renal clearance (CLR)</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B (Multiple Dose Group B5): Plasma pharmacokinetic (PK) outcome endpoint of ERX1000, AUC0-t</measure>
    <time_frame>Days 1, 7, 10, 13, 19, 22, 25, 28, 31, 33 and 37</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B (Multiple Dose Group B5): Plasma PK outcome endpoint of ERX1000, AUC0-∞</measure>
    <time_frame>Days 1, 7, 10, 13, 19, 22, 25, 28, 31, 33 and 37</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B (Multiple Dose Group B5): Plasma PK outcome endpoint of ERX1000, AUC0-τ</measure>
    <time_frame>Days 1, 7, 10, 13, 19, 22, 25, 28, 31, 33 and 37</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B (Multiple Dose Group B5): Plasma PK outcome endpoint of ERX1000, Cmax</measure>
    <time_frame>Days 1, 7, 10, 13, 19, 22, 25, 28, 31, 33 and 37</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B (Multiple Dose Group B5): Plasma PK outcome endpoint of ERX1000, trough (predose) plasma concentration (Ctrough)</measure>
    <time_frame>Days 1, 7, 10, 13, 19, 22, 25, 28, 31, 33 and 37</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B (Multiple Dose Group B5): Plasma PK outcome endpoint of ERX1000, Tmax</measure>
    <time_frame>Days 1, 7, 10, 13, 19, 22, 25, 28, 31, 33 and 37</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B (Multiple Dose Group B5): Plasma PK outcome endpoint of ERX1000, time of last measurable concentration (tlast)</measure>
    <time_frame>Days 1, 7, 10, 13, 19, 22, 25, 28, 31, 33 and 37</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B (Multiple Dose Group B5): Plasma PK outcome endpoint of ERX1000, t1/2</measure>
    <time_frame>Days 1, 7, 10, 13, 19, 22, 25, 28, 31, 33 and 37</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B (Multiple Dose Group B5): Plasma PK outcome endpoint of ERX1000, apparent total plasma clearance (CL/F)</measure>
    <time_frame>Days 1, 7, 10, 13, 19, 22, 25, 28, 31, 33 and 37</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B (Multiple Dose Group B5): Plasma PK outcome endpoint of ERX1000, apparent volume of distribution (Vz/F)</measure>
    <time_frame>Days 1, 7, 10, 13, 19, 22, 25, 28, 31, 33 and 37</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B (Multiple Dose Group B5): Plasma PK outcome endpoint of ERX1000, accumulation ratio (AR).</measure>
    <time_frame>Days 1, 7, 10, 13, 19, 22, 25, 28, 31, 33 and 37</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B (Multiple Dose Group B5): Urine PK outcome endpoint of ERX1000, amount of drug excreted in urine over the sampling period (Aeu)</measure>
    <time_frame>Days 1, 7, 10, 13, 19, 22, 25, 28, 31, 33 and 37</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B (Multiple Dose Group B5): Urine PK outcome endpoint of ERX1000, percentage of dose excreted in urine over the sampling interval (%Feu)</measure>
    <time_frame>Days 1, 7, 10, 13, 19, 22, 25, 28, 31, 33 and 37</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B (Multiple Dose Group B5): Urine PK outcome endpoint of ERX1000, renal clearance (CLR)</measure>
    <time_frame>Days 1, 7, 10, 13, 19, 22, 25, 28, 31, 33 and 37</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B (Multiple Dose Group B6): Plasma pharmacokinetic (PK) outcome endpoint of ERX1000, AUC0-t</measure>
    <time_frame>Days 1, 7, 13, 19, 25, 31, 32, 34 and 37</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B (Multiple Dose Group B6): Plasma PK outcome endpoint of ERX1000, AUC0-∞</measure>
    <time_frame>Days 1, 7, 13, 19, 25, 31, 32, 34 and 37</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B (Multiple Dose Group B6): Plasma PK outcome endpoint of ERX1000, AUC0-τ</measure>
    <time_frame>Days 1, 7, 13, 19, 25, 31, 32, 34 and 37</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B (Multiple Dose Group B6): Plasma PK outcome endpoint of ERX1000, Cmax</measure>
    <time_frame>Days 1, 7, 13, 19, 25, 31, 32, 34 and 37</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B (Multiple Dose Group B6): Plasma PK outcome endpoint of ERX1000, trough (predose) plasma concentration (Ctrough)</measure>
    <time_frame>Days 1, 7, 13, 19, 25, 31, 32, 34 and 37</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B (Multiple Dose Group B6): Plasma PK outcome endpoint of ERX1000, Tmax</measure>
    <time_frame>Days 1, 7, 13, 19, 25, 31, 32, 34 and 37</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B (Multiple Dose Group B6): Plasma PK outcome endpoint of ERX1000, time of last measurable concentration (tlast)</measure>
    <time_frame>Days 1, 7, 13, 19, 25, 31, 32, 34 and 37</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B (Multiple Dose Group B6): Plasma PK outcome endpoint of ERX1000, t1/2</measure>
    <time_frame>Days 1, 7, 13, 19, 25, 31, 32, 34 and 37</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B (Multiple Dose Group B6): Plasma PK outcome endpoint of ERX1000, apparent total plasma clearance (CL/F)</measure>
    <time_frame>Days 1, 7, 13, 19, 25, 31, 32, 34 and 37</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B (Multiple Dose Group B6): Plasma PK outcome endpoint of ERX1000, apparent volume of distribution (Vz/F)</measure>
    <time_frame>Days 1, 7, 13, 19, 25, 31, 32, 34 and 37</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B (Multiple Dose Group B6): Plasma PK outcome endpoint of ERX1000, accumulation ratio (AR).</measure>
    <time_frame>Days 1, 7, 13, 19, 25, 31, 32, 34 and 37</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B (Multiple Dose Group B6): Urine PK outcome endpoint of ERX1000, amount of drug excreted in urine over the sampling period (Aeu)</measure>
    <time_frame>Days 1, 7, 13, 19, 25, 31, 32, 34 and 37</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B (Multiple Dose Group B6): Urine PK outcome endpoint of ERX1000, percentage of dose excreted in urine over the sampling interval (%Feu)</measure>
    <time_frame>Day 1 and Day 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B (Multiple Dose Group B6): Urine PK outcome endpoint of ERX1000, renal clearance (CLR)</measure>
    <time_frame>Day 1 and Day 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B (Multiple Dose Group B5): Pharmacodynamic (PD) outcome endpoint of ERX1000, body weight</measure>
    <time_frame>Screening (Day -28 to Day -3), Days -1, 8, 15, 22, 28, 30, 33 and 37</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B (Multiple Dose Group B5): PD outcome endpoint of ERX1000, serum leptin</measure>
    <time_frame>Days -1, 7, 14, 21, 27 and 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B (Multiple Dose Group B5): PD outcome endpoint of ERX1000, serum lipid - High-density lipoprotein cholesterol (HDL)</measure>
    <time_frame>Days -1, 14 and 27</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B (Multiple Dose Group B5): PD outcome endpoint of ERX1000, serum lipid - Low-density lipoprotein cholesterol (LDL)</measure>
    <time_frame>Days -1, 14 and 27</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B (Multiple Dose Group B5): PD outcome endpoint of ERX1000, serum lipid -Total cholesterol</measure>
    <time_frame>Days -1, 14 and 27</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B (Multiple Dose Group B5): PD outcome endpoint of ERX1000, serum lipid - Triglyceride</measure>
    <time_frame>Days -1, 14 and 27</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B (Multiple Dose Group B5): PD outcome endpoint of ERX1000, serum insulin</measure>
    <time_frame>Days 7 and 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B (Multiple Dose Group B5): PD outcome endpoint of ERX1000, assessment derived from oral glucose tolerance test (OGTT) - serum glucose</measure>
    <time_frame>Days -1, 14 and 27</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B (Multiple Dose Group B5): PD outcome endpoint of ERX1000, assessment derived from oral glucose tolerance test (OGTT) - serum insulin</measure>
    <time_frame>Days -1, 14 and 27</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B (Multiple Dose Group B5): PD outcome endpoint of ERX1000, derived from oral glucose tolerance test (OGTT) - Homeostatic Model Assessment of Insulin Resistance</measure>
    <time_frame>Days -1, 14 and 27</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B (Multiple Dose Group B5): PD outcome endpoint of ERX1000, assessments derived from oral glucose tolerance test (OGTT) - Matsuda Index</measure>
    <time_frame>Days -1, 14 and 27</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B (Multiple Dose Group B6):Pharmacodynamic (PD) outcome endpoint of ERX1000, body weight</measure>
    <time_frame>Screening (Day -28 to -3), Days -1, 8, 15, 22, 28, 30, 34 and 37</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B (Multiple Dose Group B6):PD outcome endpoint of ERX1000, serum leptin</measure>
    <time_frame>Day -1, 7, 14, 21, 27 and 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B (Multiple Dose Group B6): PD outcome endpoint of ERX1000, serum lipid - High-density lipoprotein cholesterol (HDL)</measure>
    <time_frame>Day -1, 14 and 27</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B (Multiple Dose Group B6): PD outcome endpoint of ERX1000, serum lipid - Low-density lipoprotein cholesterol (LDL)</measure>
    <time_frame>Day -1, 14 and 27</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B (Multiple Dose Group B6): PD outcome endpoint of ERX1000, serum lipid -Total cholesterol</measure>
    <time_frame>Day -1, 14 and 27</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B (Multiple Dose Group B6): PD outcome endpoint of ERX1000, serum lipid - Triglyceride</measure>
    <time_frame>Day -1, 14 and 27</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B (Multiple Dose Group B6):PD outcome endpoint of ERX1000, serum insulin</measure>
    <time_frame>Days 7 and 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B (Multiple Dose Group B6):PD outcome endpoint of ERX1000, assessment derived from oral glucose tolerance test (OGTT) - serum glucose</measure>
    <time_frame>Days -1, 14 and 27</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B (Multiple Dose Group B6):PD outcome endpoint of ERX1000, assessment derived from oral glucose tolerance test (OGTT) - serum insulin</measure>
    <time_frame>Days -1, 14 and 27</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B (Multiple Dose Group B6):PD outcome endpoint of ERX1000, assessment derived from oral glucose tolerance test (OGTT) - Homeostatic Model Assessment of Insulin Resistance</measure>
    <time_frame>Days -1, 14 and 27</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B (Multiple Dose Group B6):PD outcome endpoint of ERX1000, assessments derived from oral glucose tolerance test (OGTT) - Matsuda Index</measure>
    <time_frame>Days -1, 14 and 27</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>ERX1000</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ERX1000 powder provided for preparation of a 4 mg/10 mL oral suspension&#xD;
Proposed dose level for Part A: 4 mg&#xD;
Proposed dose level for Part B: 4 mg. The dose administered will not exceed the highest dose administered in Part A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Reference product: Magnesium hydroxide carbonate powder prepared in an oral suspension</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ERX1000</intervention_name>
    <description>ERX1000 powder provided for preparation of a 4 mg/10 mL oral suspension</description>
    <arm_group_label>ERX1000</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A suspension containing magnesium hydroxide carbonate in polysorbate</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Magnesium hydroxide carbonate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able to comprehend and willing to sign an informed consent form (ICF) and to abide by&#xD;
             the study restrictions.&#xD;
&#xD;
          -  Adult females and males, of any race, between 18 and 55 years of age, inclusive, at&#xD;
             Screening.&#xD;
&#xD;
          -  Females of non-childbearing potential, which is defined as permanently sterile (ie,&#xD;
             due to hysterectomy, bilateral salpingectomy, or bilateral oophorectomy), or with&#xD;
             bilateral tubal ligation or Essure® (hysteroscopic bilateral tubal occlusion) with&#xD;
             confirmation of occlusion of the fallopian tubes performed at least 3 months prior to&#xD;
             Screening, or postmenopausal (defined as at least 12 months post cessation of menses&#xD;
             without an alternative medical cause and follicle-stimulating hormone [FSH] level&#xD;
&#xD;
             ≥ 40 mIU/mL). Males will agree to use contraception and refrain from sperm donation.&#xD;
&#xD;
          -  Body mass index between 30.0 and 39.9 kg/m^2, inclusive, at Screening.&#xD;
&#xD;
          -  Glycosylated hemoglobin (HbA1c) level of &lt; 6.5% at Screening (test may be repeated&#xD;
             once for confirmation of out-of-range values).&#xD;
&#xD;
          -  Vital signs at Screening and Check-in as per the following ranges and stable (measured&#xD;
             in a supine position after a minimum of 5 minutes of rest):&#xD;
&#xD;
               1. Systolic blood pressure ≥ 90 and ≤ 140 mmHg&#xD;
&#xD;
               2. Diastolic blood pressure ≥ 50 and ≤ 90 mmHg&#xD;
&#xD;
               3. Pulse rate ≥ 50 and ≤ 100 bpm&#xD;
&#xD;
          -  In good health, determined by no clinically significant findings from medical history,&#xD;
             physical examination, 12-lead ECG, vital sign measurements, and clinical laboratory&#xD;
             evaluations at Screening and/or Check-in as assessed by the Investigator (or&#xD;
             designee).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks&#xD;
             prior to dose administration on Day 1.&#xD;
&#xD;
          -  Significant history or clinical manifestation of any metabolic, allergic,&#xD;
             dermatological, hepatic, renal, hematological, pulmonary, cardiovascular,&#xD;
             gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as&#xD;
             determined by the Investigator (or designee).&#xD;
&#xD;
          -  Obesity induced by known endocrine or genetic disorders (eg, Cushing syndrome,&#xD;
             hypothyroidism, Prader Willi syndrome).&#xD;
&#xD;
          -  Any previous surgical treatment or procedures with medical devices (such as insertion&#xD;
             of lap band or gastric balloons) for obesity (excluding liposuction if performed &gt; 1&#xD;
             year prior to Check-in).&#xD;
&#xD;
          -  History of significant hypersensitivity, intolerance, or allergy to any drug compound,&#xD;
             food, or other substance, which would increase the subject's risk of participation.&#xD;
&#xD;
          -  History of stomach or intestinal surgery or resection that would potentially alter&#xD;
             absorption and/or excretion of orally administered drugs (uncomplicated appendectomy,&#xD;
             cholecystectomy, and hernia repair &gt; 6 months prior to Screening will be allowed).&#xD;
&#xD;
          -  History or evidence of underlying liver disease, including viral (hepatitis B and C)&#xD;
             or alcoholic hepatitis, or confirmed diagnosis of nonalcoholic steatohepatitis (NASH);&#xD;
             nonalcoholic fatty liver disease (NAFLD) with qualifying liver function tests (LFTs)&#xD;
             will be allowed.&#xD;
&#xD;
          -  Gilbert's Syndrome (congenital non-hemolytic hyperbilirubinemia) or suspicion of&#xD;
             Gilbert's Syndrome based on total and direct bilirubin.&#xD;
&#xD;
          -  Laboratory results that exceed the following thresholds at Screening AND Check-in&#xD;
             (laboratory tests may be repeated once for confirmation of out-of-range values) as&#xD;
             specified:&#xD;
&#xD;
               1. alanine aminotransferase (ALT) &gt; 1.5 × upper limit of normal (ULN)&#xD;
&#xD;
               2. aspartate aminotransferase (AST) &gt; 1.5 × ULN&#xD;
&#xD;
               3. gamma glutamyl transferase (GGT), alkaline phosphatase (ALP), total bilirubin, or&#xD;
                  International Normalized Ratio (INR) &gt; ULN&#xD;
&#xD;
               4. Hemoglobinopathy, hemolytic anemia, or chronic anemia (hemoglobin concentration &lt;&#xD;
                  13.0 g/dL [130 g/L] for males, &lt; 11.0 g/dL [110 g/L] for females) at Screening or&#xD;
                  any other condition known to interfere with interpretation of HbA1c measurement&#xD;
&#xD;
               5. Neutrophils &lt; 1.5 × 109/L deemed clinically significant by Investigator upon a&#xD;
                  confirmatory repeat&#xD;
&#xD;
               6. Thyroid-stimulating hormone (TSH) level above the normal range, confirmed on&#xD;
                  repeat&#xD;
&#xD;
          -  History or presence of cardiac arrhythmia (at the discretion of the Investigator) or&#xD;
             congenital long QT syndrome.&#xD;
&#xD;
          -  A QT interval corrected for heart rate using Fridericia's method (QTcF) &gt; 450 msec for&#xD;
             males or &gt; 470 msec for females on Screening ECG. At the discretion of the&#xD;
             Investigator, ECG may be repeated twice and an average taken of the 3 readings.&#xD;
&#xD;
          -  The subject has creatinine clearance ≤ 80 mL/minute as calculated using the&#xD;
             Cockroft-Gault equation. At the discretion of the Investigator, evaluation may be&#xD;
             repeated once to confirm.&#xD;
&#xD;
          -  History of alcoholism or drug/chemical abuse within 2 years prior to Check in.&#xD;
&#xD;
          -  Alcohol consumption of &gt; 14 units per week. One unit of alcohol equals 12 oz (360 mL)&#xD;
             of beer, 1½ oz (45 mL) of liquor, or 5 oz (150 mL) of wine.&#xD;
&#xD;
          -  Positive urine drug screen at Screening; or positive alcohol breath test result or&#xD;
             positive urine drug screen at Check-in.&#xD;
&#xD;
          -  Positive hepatitis B surface antigen and/or hepatitis C antibody and/or positive human&#xD;
             immunodeficiency virus 1/2 (Appendix 2).&#xD;
&#xD;
          -  Participation in a clinical study involving administration of an investigational drug&#xD;
             (new chemical entity) in the past 30 days or 5 half-lives prior to dosing, whichever&#xD;
             is longer.&#xD;
&#xD;
          -  Subjects who are actively dieting, have gained or lost &gt; 5 pounds, or using or intend&#xD;
             to use any prescription or nonprescription drugs for weight loss including herbal or&#xD;
             other dietary supplements within 3 months prior to Check-in.&#xD;
&#xD;
          -  Use or intend to use any medications/products known to alter drug absorption,&#xD;
             metabolism, or elimination processes, including St. John's wort, within 30 days prior&#xD;
             to Check-in and throughout the outpatient Follow-up period.&#xD;
&#xD;
          -  Use or intend to use any prescription medications/products within 30 days prior to&#xD;
             Check-in, unless deemed acceptable by the Investigator (or designee).&#xD;
&#xD;
          -  Use or intend to use slow-release medications/products considered to still be active&#xD;
             within 14 days prior to Check-in, unless deemed acceptable by the Investigator (or&#xD;
             designee).&#xD;
&#xD;
          -  Use or intend to use any nonprescription medications/products including vitamins,&#xD;
             minerals, and phytotherapeutic/herbal/plant-derived preparations within 14 days prior&#xD;
             to Check-in and throughout the outpatient Follow-up period, unless deemed acceptable&#xD;
             by the Investigator (or designee).&#xD;
&#xD;
          -  Consumption of alcohol from 72 hours prior to Check-in.&#xD;
&#xD;
          -  Use of tobacco- or nicotine-containing products (including nicotine and non-nicotine&#xD;
             e-cigarettes, vaping, etc.) within 3 months prior to Check-in, or positive cotinine at&#xD;
             Screening or Check-in.&#xD;
&#xD;
          -  Receipt of blood products within 2 months prior to Check-in.&#xD;
&#xD;
          -  Donation of blood from 8 weeks prior to Screening, plasma from 2 weeks prior to&#xD;
             Screening, or platelets from 6 weeks prior to Screening.&#xD;
&#xD;
          -  Poor peripheral venous access.&#xD;
&#xD;
          -  Have previously completed or withdrawn from this study or any other study&#xD;
             investigating ERX1000, and have previously received the investigational product.&#xD;
&#xD;
          -  Subjects who, in the opinion of the Investigator (or designee), should not participate&#xD;
             in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Irene Mirkin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Teo Uysal</last_name>
    <phone>(617) 335-5778</phone>
    <email>teo@erxpharmaceuticals.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Covance Clinical Research Unit Inc.</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Irene Mirkin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 7, 2021</study_first_submitted>
  <study_first_submitted_qc>May 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2021</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ERX1000</keyword>
  <keyword>Obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Hydroxide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

